Registration Statement · S-1
Hemab Therapeutics Holdings, Inc.
COAGNASDAQEQUITYCurrent
Registration Statement
Company context
We are a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. Our mission is to build the leading coagulation company by discovering, developing, and commercializing innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases. Coagulation disorders encompass a broad and heterogeneous group of conditions, and many patients experience significant life-long disease burden due to either a lack of available prophylactic therapies or limitations associated with existing treatment approaches.
Current securities
As-filed source
As filedOpen full document ↗